HDAC Inhibitor Phase I Trial in Advanced Cancer - PCYC-0402

This study is ongoing; however, enrollment is closed.

      To access the most up-to-date information on this study,
      please refer to this page at ClinicalTrials.gov.

Official Title

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer

Purpose

This study seeks to determine the highest dose of PCI-24781 that can be taken without causing serious side effects in patients with advanced cancer. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.

Study Design

In the Phase 1 dose escalation study, up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2, up to 90 mg/m2 , 2 or 3 times a day according to 3 different dosing schedules within 28 day cycle until the maximum tolerated dose is reached.

For additional detail on this study, please refer to the information posted on ClinicalTrials.gov.
You may contact Pharmacyclics Medical Affairs by email at MedicalAffairs@pcyc.com or 1.408.774.0330.